FDA Website - ACLA President to Testify on Regulation of Diagnostic Tests The "2024-03-21_FDA Website - ACLA President to Testify on Regulation of Diagnostic Tests" document summarizes ACLA’s argument that treating most lab testing services as medical devices would reduce access to critical tests, raise costs, and hinder innovation, and points to ACLA’s prior comments urging withdrawal of the rule and advocating for legislation to establish a diagnostics-specific framework. primary file regulatory ldts 2024-03-21_FDA Website - ACLA President to Testify on Regulation of Diagnostic Tests.md regulatory/ldts/2024-03-21_FDA Website - ACLA President to Testify on Regulation of Diagnostic Tests.md 2024_03_21 date converted 2024-06-03 website Public Domain 198 381 gfile-url xfile-github-download-url pdf-gdrive-url pdf-github-url github-markdown-url github-markdown-download-url web-pdf-url web-slides-url youtube-url web-url